BOLD

Boundless Bio, Inc.

Boundless Bio, Inc. (BOLD) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B+ (3.7) C+ (2.8) C- (1.9) B (3.4) C+ (2.6) B- (2.9)
2026-11-10 A- (3.9) B- (2.9) C+ (2.5) B+ (3.5) C+ (2.6) B- (3.1)
2026-11-03 B+ (3.7) B- (2.9) C+ (2.5) B+ (3.6) C+ (2.7) B- (3.1)
2026-10-27 B+ (3.7) C+ (2.8) C+ (2.5) B+ (3.7) C+ (2.6) B- (3.1)
2026-10-20 B+ (3.7) C+ (2.8) C+ (2.5) B+ (3.6) C+ (2.6) B- (3.1)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe